Biphenotypic acute leukaemia: A case series

Author(s): Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, et al.

Abstract

Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

Similar Articles

A classification of acute leukemia for the 1990s

Author(s): Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, et al.

Lineage commitment in biphenotypic acute leukemia Leukemia 7: 919-927

Author(s): Buccheri V, Matutes E, Dyer MJ, Catovsky D

Proposals for the immunological classification of acute leukemias

Author(s): Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, et al.

Philadelphia chromosome positive acute myeloid leukemia: cytoimmunologic and cytogenetic features

Author(s): Cuneo A, Ferrant A, Michaux JL, Demuynck H, Boogaerts M, et al.

Cytogenetic findings in acute biphenotypic leukaemia

Author(s): Carbonell F, Swansbury J, Min T, Matutes E, Farahat N, et al.

Adult T-biphenotypic acute leukaemia: Clinical and biological features and outcome

Author(s): Rubio MT, Dhedin N, Boucheix C, Bourhis JH, Reman O, et al.

Acute mixed lineage leukemia in children: The experience of St Jude Childrens Research Hospital

Author(s): Rubnitz JE, Onciu M, Pounds S, Shurtleff S, Cao X, et al.